Greener Blood Processing: How a New Filter Eliminates Harmful Chemical Waste

Greener Blood Processing: How a New Filter Eliminates Harmful Chemical Waste

2026-11-18 companies

Washington, Wednesday, 18 November 2026.
Sangtech Lab has launched the world’s first commercial inline blood filter produced without organic solvents or wastewater, setting a clean-manufacturing standard that slashes environmental compliance costs for medical supply chains.

A Decades-Old Innovation Reimagined for Sustainability

For 30 years, leukoreduction filters in blood processing have relied on wet chemistry techniques involving organic solvents such as ethanol, acetone, and tert-butanol to remove white blood cells from donated blood prior to transfusion [1][2]. These conventional methods, while effective, have long contributed to environmental and operational challenges, including hazardous chemical handling, wastewater generation, and elevated compliance costs within medical device supply chains [GPT]. Sangtech Lab Inc., a Taipei-based medtech innovator, has now disrupted this entrenched process with the launch of CellNet™ PR, the world’s first commercial whole blood inline leukoreduction filter manufactured without organic solvents or process wastewater [1][2].

Engineering a Cleaner Manufacturing Breakthrough

At the heart of the innovation is a patented supercritical carbon dioxide (CO₂) process, protected under U.S. Patent No. 11,224,686 B2, which replaces traditional solvent-based methods with a closed-loop system that recovers and reuses CO₂ [1][2]. This process achieves a measured gate-to-gate carbon footprint of 7.68 kg CO₂e per kilogram of filtration media, a substantial reduction compared to conventional solvent-dependent manufacturing pathways [1]. Tyler McConville, Deputy CEO of Sangtech Lab, emphasized the significance of this shift: ‘The leukocyte filter was treated as a solved problem for thirty years, and we did not accept that. We went back to how the filter is actually made. Taking out the solvents and the wastewater is not a trade-off against performance. It is a cleaner filter and a cleaner process at the same time, and it makes CellNet™ PR the most sustainable leukoreduction filter in the world.’ [1]

Performance Meets Environmental Responsibility

CellNet™ PR is not only environmentally sustainable but also clinically robust. The filter achieves residual white cell counts below 0.3×10⁶ per unit, red blood cell recovery rates exceeding 92%, and 98–100% platelet removal without activation [1]. It is manufactured under ISO 13485 standards and carries ISO 10993-5 cytotoxicity grade 0 certification, ensuring compatibility with stringent medical device biocompatibility requirements [2][3]. Additionally, CellNet™ PR features both zero-DEHP hard and soft housing options, and DEHP-free filtration media, aligning with the European Union’s 2030 sunset timeline for DEHP in medical devices [1][2].

Global Recognition and Commercial Readiness

The launch of CellNet™ PR follows its commercialization in 2025 at Sangtech’s ISO 13485-certified manufacturing facility in Yilan, Taiwan, where research on supercritical fluid media modification began in 2016 [2][3]. The technology has since garnered significant industry validation, including a 2026 Edison Silver Award in the Energy & Climate Resiliency category and a 2026 R&D 100 Award in Process and Prototyping [1][2][5]. CellNet™ PR models—PR 250 and PR 500—are now available for global procurement, offering leukocyte and platelet removal for whole blood applications [1][2]. Sangtech’s innovation signals a shift in medtech manufacturing, where sustainability and clinical performance are no longer mutually exclusive.

Sources


Biotechnology Medical Devices